A Trial of Academic Detailing to Promote Prescribing of Biosimilars

The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.

NCT Number	NCT07221890
Lead Sponsor	Brigham and Women's Hospital Collaborators: Humana Healthcare Research, Inc.
Conditions	Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Psoriasis (PsO)
Enrollment	1,325 participants
Start Date	2025-11-06
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-14